Clinical Development

VASTox plc
23 May 2007



                                   VASTox plc

                          ("VASTox" or "the Company")



 VASTOX PREPARES TO COMMENCE NEXT PHASE OF CLINICAL DEVELOPMENT FOR TWO LEADING
                         NEURO-DISORDER DRUG PROGRAMMES


                Progress follows earlier positive clinical data



Oxford, UK, 23 May 2007 - VASTox plc (AIM: VOX), a leading UK biotechnology
company, announces that the Company is preparing to commence the next set of
clinical trials in its two leading neuro-disorder programmes, which target two
symptoms of Parkinson's disease.

This development follows positive results from initial Phase I studies of the
small molecule drug candidates, which show them not only to be safe but also to
significantly suppress saliva and sebum production, the causes of two
distressing symptoms in Parkinson's disease, sialorrhoea (drooling) and
seborrhoea (greasy skin) respectively.  The results from the sebum study were so
pronounced, with a reduction in sebum production of 70%, that it has led VASTox
to investigate this clinical candidate as a potential treatment in the
multi-billion dollar acne market.

Both programmes were previously owned by DanioLabs, which was acquired by VASTox
in March 2007, and the progression of these clinical programmes follows a
successful period of integration into the scientific and commercial
infrastructure of the enlarged Company.

The two programmes were developed using the Company's expertise in drug
reprofiling, which is based on combining clinical observations with the results
of screening drugs through zebrafish disease models.  In these two programmes,
this reprofiling approach has found two new indications for established drugs
with a history of safe use but it is equally valid for drugs that have failed to
reach the market due to low efficacy against their original indications.

In the seborrhoea programme, recruitment for the next Phase I clinical trial is
underway and VASTox expects to begin this in mid 2007.  In sialorrhoea, a
combined Phase I/II clinical trial in patients will commence in the fourth
quarter of 2007.

Steven Lee, PhD, CEO of VASTox commented "The deal to acquire DanioLabs earlier
this year provided VASTox with a broader drug pipeline, which includes
candidates at the clinical and preclinical stages of development, as well as a
strong and growing patent estate to protect these drug programmes in key
markets.  These two lead Phase I programmes have now been fully integrated into
the enlarged Company and work to continue the next phase of development in
conjunction with strong commercial activity is underway."


                                    - ends -


For more information please contact:


VASTox

Steven Lee, PhD, Chief Executive Officer               Tel: [phone]
Darren Millington, ACMA, Chief Financial Officer

Citigate Dewe Rogerson
Mark Swallow / David Dible / Valerie Auffray           Tel: [phone]

Evolution Securities
Neil Eliott / Tim Worlledge                            Tel: [phone]


About VASTox plc

VASTox is a leading UK biotechnology company that discovers and develops
proprietary new drugs. The Company's internal drug development programmes are
underpinned by its advanced chemistry and drug screening (chemical genomics)
technology platforms, which it also provides on a collaborative or
fee-for-service basis to the pharmaceutical industry.

VASTox has a broad range of drug discovery programmes in the clinical,
pre-clinical and discovery stages of development, which target serious diseases
with a high unmet medical need. These therapeutic areas include neuro-disorders
(neurodegenerative and neuromuscular), anti-infectives, ophthalmic diseases,
oncology and regenerative medicines.

VASTox's in-house drug development capabilities combine world-class expertise in
both medicinal and carbohydrate chemistry with high-volume, high-content
screening using its proprietary zebrafish and fruitfly technologies (chemical
genomics). These whole organism screens have the potential to dramatically
decrease the time and cost of drug discovery and development by delivering data
that are highly predictive of the efficacy and toxicity of potential drug
compounds in humans.

The company listed on the AIM market of the London Stock Exchange in October
2004 - symbol: VOX

Further information about the company is available at www.vastox.com

This document contains "forward-looking statements" within the meaning of the
U.S. Private Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by words such as "anticipates", "intends", "plans",
"seeks", "believes", "estimates", "expects" and similar references to future
periods, or by the inclusion of forecasts or projections.

Forward-looking statements are based on the Company's current expectations and
assumptions regarding our business, the economy and other future conditions.
Because forward-looking statements relate to the future, by their nature, they
are subject to inherent uncertainties, risks and changes in circumstances that
are difficult to predict. The Company's actual results may differ materially
from those contemplated by the forward-looking statements. The Company cautions
you therefore that you should not rely on any of these forward-looking
statements as statements of historical fact or as guarantees or assurances of
future performance. Important factors that could cause actual results to differ
materially from those in the forward-looking statements and regional, national,
global political, economic, business, competitive, market and regulatory
conditions.





                      This information is provided by RNS
            The company news service from the London Stock Exchange




END

NRAATMRTMMTTBMR